New York, NY (Vocus) September 8, 2009
Thomson Reuters, one of the world’s largest stock market analytics firms which is also ranked as one of Britain’s most respected companies, has singled out NutraPharma shares as likely to outperform the market based on its “proprietary quantitative model”. Reuter’s description of what this "technical" ranking means is quoted below.
“We cannot guarantee that each stock will perform in accordance with its rank. But we do believe that over the long term, stocks rated Outperform (30% of all stocks we rate) will, in the aggregate, outperform stocks rated Neutral (40% of all stocks we rate), and that stocks rated Neutral will, in the aggregate, outperform stocks rated Underperform (30%). All analysis is based on publicly available company financials, fundamental ratios, relative rankings of financial data and ratios, and observed equity prices”
See the report here: http://www.undiscoveredequities.com/nphc_reuters.pdf
Undiscovered Equities is currently offering a complimentary trial subscription.
To view our newsletter on a complimentary trial basis and take advantage of our other services go to http://www.undiscoveredequities.com and join our email list on our home page.
# # #